Wang Jue, Gillaspie Caitlynn, Kunadharaju Rajesh, Talmon Geoffrey A, Enke Charles
Department of Internal Medicine, Section of Oncology-Hematology, University of Nebraska Medical Center, Omaha, Nebraska 68198-7680, USA.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198-3135, USA.
World J Oncol. 2011 Aug;2(4):175-180. doi: 10.4021/wjon370w. Epub 2011 Aug 24.
Sarcomatoid bladder cancer is a rare and aggressive variant of urothelial carcinoma.
A retrospective review of our experience in managing patients with sarcomatoid bladder cancer (SRBC) between 1997 and 2011 was performed to better define the behavior and outcomes of this disease.
The median age of the patients was 63 years. All patients presented with high grade histology. Eighty-five percent of the patients presented with muscle invasive disease and fifty percent presented with stage IV carcinoma. Ten of 14 (71%) of patients underwent a cystectomy. Patients with SRBC was younger (P < 0.01), more commonly presented with higher grade histology (P < 0.01) and advanced stage disease (P < 0.01), in comparison with patients with Urothelial carcinoma (UC). At a median follow-up of 7 months (range 1.3 - 112), five (35.7%) patients have died in last follow-up. Two-year survival was 53.5%. Three patients with long term survival were reported.
Sarcomatoid bladder cancer is associated with poor prognosis. Multimodality therapy may improve these patients outcome.
肉瘤样膀胱癌是尿路上皮癌的一种罕见且侵袭性强的变异型。
对1997年至2011年间我们治疗肉瘤样膀胱癌（SRBC）患者的经验进行回顾性分析，以更好地明确该疾病的行为和预后。
患者的中位年龄为63岁。所有患者的组织学分级均为高级别。85%的患者表现为肌层浸润性疾病，50%的患者表现为IV期癌。14例患者中有10例（71%）接受了膀胱切除术。与尿路上皮癌（UC）患者相比，SRBC患者更年轻（P < 0.01），更常表现为高级别组织学（P < 0.01）和晚期疾病（P < 0.01）。中位随访7个月（范围1.3 - 112个月）时，5例（35.7%）患者在末次随访时死亡。两年生存率为53.5%。报告了3例长期生存患者。
肉瘤样膀胱癌预后较差。多模式治疗可能改善这些患者的预后。
